Advertisement
Advertisement
U.S. Markets open in 3 hrs 6 mins
Advertisement
Advertisement
Advertisement
Advertisement

BioLife Solutions, Inc. (BLFS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
38.16-13.55 (-26.20%)
At close: 04:00PM EST
38.16 0.00 (0.00%)
After hours: 04:40PM EST
Advertisement
Sign in to post a message.
  • R
    Rodd
    Should've hung on to this stock but made a decent profit. Good pick and shovel play in the biotech sector. I'll buy in again longterm if it continues to pull back.
  • T
    Tata
    Not a lot people know about this jewel. I am a longtime fan of this awesome company and it never disappoints. Add it to your portfolio and you will be rewarded so much return!
    Bullish
  • T
    Truky47
    Only think going on with this stock is management dumping shares
    prior to the next earnings call
    Bearish
  • L
    Long Term
    15X revenues - still great short? How did it get so overvalued?
  • b
    black panther
    Last evening's call shows brighter color to Zacks Regarding the commercial cell therapy company that has been validating our evo platform, I'm very pleased to report that this work has been successfully completed, and we're working to gain approval to disclose the company name and other details.

    Turning to our CBS freezer franchise. I'll remind you that COVID-19 has impacted us in 2 ways. And travel and on-site visitor restrictions at customer and prospect sites, and also a delay in approvals for large capital equipment purchases, despite this environment, we gained 23 new customers that purchased freezers or related accessories in the third quarter. Key CBS customers in Q3 include AskBio, Enlightened Therapeutics, Novavax and Neuvogen. Other key customers that bought CBS products in 2020 include Athersys, BlueRock Therapeutics, Celgene, Fate Therapeutics, Kite Pharma, Lonza and VWR.

    Product development on 2 new freezer platforms is continuing, and we anticipate launches in Q1. We're also making good progress to vertically integrate and use our talented design and engineering teams at CBS to manufacture the evo dry vapor shippers for our cold chain management platform. We expect to introduce CBS [made doers] [ph] in the first half of next ye
  • b
    black panther
    On November 30, 2020, the board of directors (the “Board”) of BioLife Solutions, Inc., (the “Company”) accepted the resignation of Mr. Thomas Girschweiler, an investor and stockholder of the Company for the past twenty five years, as a member of the Board effective December 1, 2020. Mr. Girschweiler resigned in order to focus on other personal interests. Mr. Girschweiler did not advise the Company that his resignation was the result of any disagreement with the Company on any matter relating to its operations, policies or practices.

    The Company has retained Spencer Stuart, a leading executive and board search firm, to identify potential replacement candidates to fill Mr. Girschweiler’s seat on the Board, with a focus on diverse candidates to support the Company’s desire to diversify the composition of the Board.

    In a separate transaction, Mr. Girschweiler agreed to sell 1,600,000 shares of the Company’s common stock to Casdin Capital in a private transaction.
    Bullish
  • T
    Truky47
    14% drop over the last few weeks...fueled today by BLFS Exec selling 20K+ shares
    He's know now is the time to sell vs in a few days when 10million shares used to pay
    for acquisitions will become unrestricted and hit the market. This will be like a
    python trying to swallow a pig and we could see the stock back in the low 40s
    Aint going to be pretty
    Neutral
  • C
    CalifTown
    The hardest task an investor has to exercise is patience. Many of them would have been millionaires.
    Volatility is expected from micro-cap stocks. The lower the float the higher the volatility. We have seen this before and BLFS is no exception. Nothing new has happened to suggest the over all upward direction of the price is going to change. What's new is more BUY rating and one actually has raised the target to $23.
    Patience.
  • b
    black panther
    Dec. 16, 2020-- Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission has granted conditional marketing authorization for Tecartus™ (autologous, anti-CD19-transduced CD3+ cells; formerly KTE-X19). Tecartus is a chimeric antigen receptor (CAR) T cell therapy for adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. Conditional authorization is granted in the interest of public health where the benefit of immediate availability outweighs the risk of less comprehensive data available.
    Bullish
  • C
    Casey
    Love this stock. Minor speed bump last couple months, but it's chugging along again now
    Bullish
  • J
    John A
    Looks like we need some more time backing and filling or sideways movement before breaking out to the upside. When we get a triple top breakout we should see another 8-12 points of movement. Stay thirsty my friends.
  • J
    John A
    Good backing and filling today. Support as low as 18.01, triple top breakout would be at 23 for thoughs waiting for a new buy signal. The minimum target price would be 29 on the breakout. Good fundamental news each quarter over the next year or so.
  • J
    John A
    Higher lows was the answer, not a head and shoulders. Finally finished with backing and filling. Notice that the volume has picked up also, a good sign. BLFS is being noticed by more investors. Don’t see a buyout here. Why not buyout at 10, 15, or 20 per share. P&F charts show price target in a range between 28-47 per share sometime in the future, depending on a horizontal or vertical count. It will not be a straight shot but a zig-zag higher with backing and filling occurring. Great job to all that are still long. Wish BLFS had options.
  • J
    John A
    Victor has been correct. Notice how the volume has picked up as the price moves higher. Notice how the volume dries up as the price goes down. Remember there is a buyer for every seller no matter where the price is. Over time it seems that the price of BLFS will push higher. Just be patient, still believe we will see the price in the 40’s next year.
  • V
    Victor
    For the past 10 weeks Monday has correctly indicated the direction blfs has gone every single week. Red Monday meant a Red week and vice versa Green Monday meant a Green week. You could of made a lot of extra gains in hindsight if noticed earlier on. See what monday does and you either buy before close when green, then sell before close on friday. Or stay out for the week when red on Monday. 10 weeks and counting. Everyone better hope for a green Monday.
  • J
    John A
    Top out in Oct. or build a base until Oct. and then resume our upward move.
  • P
    Paneristi
    Nice earnings and margins
  • M
    Matthew
    Nice move up with high volume. Looks like we're headed above $7.00 tomorrow.
  • Y
    Yiannis
    From +8% to minus within the day. It is hard to understand what is going on with this stock.
  • r
    reed
    BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million, with total 2021 revenue of $101 million to $110 million.

    BioLife also announced that Stirling has expanded its existing partnership with a leading global contract development and manufacturing organization (CDMO) and has been selected by this customer as their preferred provider of ULT storage across their multiple business units. Stirling will supply approximately 100 energy-efficient ULT mechanical freezers to support this customer's cold chain capabilities for biologics and emerging modalities. This augments the existing installed base of 200 Stirling freezers across this CDMO's worldwide facilities footprint.
    Bullish
Advertisement
Advertisement